- Home
- MREO vs OFS Comparison
MREO vs OFS Comparison
Compare MREO & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MREO | OFS |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 54.3M |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MREO | OFS |
|---|---|---|
| Price | $0.25 | $3.93 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 45.8K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 16.83% |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $5,184.20 | N/A |
| Revenue Next Year | $55.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $2.72 |
| 52 Week High | $2.37 | $8.99 |
Technical Indicators
Market Signals| Indicator | MREO | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 36.56 | 59.56 |
| Support Level | $0.22 | $3.26 |
| Resistance Level | $0.35 | $4.06 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 12.61 | 75.89 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.